Pfizer and Merck: Earnings Face-Off
Pfizer and Merck have done a good job beating Wall Street's per-share expectations in the face of real headwinds. Pfizer has gone through a dramatic reorganization to fight this challenge, while Merck is standing pat with its more diverse business model.
In this video, health-care analyst David Williamson discusses both companies second-quarter results in greater detail, how their different approaches are working out, and what key drugs in their respective pipelines investors should focus on.
One of the best parts of owning big pharma stocks is their attractive dividends, but smart investors know the importance of diversifying -- seeking high-yielding stocks from multiple industries. The Motley Fool's special free report "Secure Your Future With 9 Rock-Solid Dividend Stocks" outlines the Fool's favorite dependable dividend-paying stocks across all sectors. Grab your free copy by clicking here.
The article Pfizer and Merck: Earnings Face-Off originally appeared on Fool.com.
David Williamson owns shares of Pfizer, Zoetis, and Merck. Follow David on Twitter: @MotleyDavid.The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.